A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’” - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Clarification on the Letter Addressing the Indirect Comparison of Long-Term Efficacy Between Tralokinumab and Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Patients
To clarify the rationale for performing an anchored indirect comparison of tralokinumab and lebrikizumab in the treatment of moderate-to-severe atopic dermatitis.
Approach:
Response to Concerns: Addressed concerns raised by Rand et al. regarding the comparability of week 16 responders and the implications of trial design differences.
Methodology Explanation: Explained the use of an anchored MAIC to mitigate bias and compared baseline and week 16 characteristics.
Key Findings:
The claim that lebrikizumab has greater off-drug durability is based on data that did not use the marketed formulation of tralokinumab.
Interpretation:
The analysis aimed to provide a framework for comparing tralokinumab and lebrikizumab while recognizing inherent limitations and biases.
Limitations:
Potential differences in off-drug durability between treatments may affect the validity of the withdrawal arms as comparators.
Some baseline characteristics could not be adjusted for due to lack of quantifiable data, which limits the analysis.
Conclusion:
The analysis highlights the limitations of the comparison between tralokinumab and lebrikizumab, suggesting caution in interpreting the findings.
Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.
